Safety and Efficacy of AR1005 in Patients with Lewy Body Disease

AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.

Matching placebo for AR1005 to be administered BID for 20 weeks

3mg Rivastigmine will be administered BID for both active and placebo groups